(NASDAQ: MRNS) Marinus Pharmaceuticals's forecast annual revenue growth rate of 61.5% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Marinus Pharmaceuticals's revenue in 2024 is $28,288,000.On average, 5 Wall Street analysts forecast MRNS's revenue for 2024 to be $2,165,489,371, with the lowest MRNS revenue forecast at $1,868,297,654, and the highest MRNS revenue forecast at $2,933,463,532. On average, 5 Wall Street analysts forecast MRNS's revenue for 2025 to be $3,380,624,452, with the lowest MRNS revenue forecast at $2,461,033,075, and the highest MRNS revenue forecast at $4,938,546,283.
In 2026, MRNS is forecast to generate $7,032,621,747 in revenue, with the lowest revenue forecast at $5,877,913,818 and the highest revenue forecast at $7,520,433,661.